Treatment of Leiomyomata With the Selective Progesterone Receptor Modulator CDB-2914 [ulipristal].

Trial Profile

Treatment of Leiomyomata With the Selective Progesterone Receptor Modulator CDB-2914 [ulipristal].

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2012 Additional lead trial investigator (Lynnette K Nieman) identified as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual patient number (57) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top